Alicia Ciccone

While evidence-based guidelines exist for the determination of brain death in infants, children, and adults, Nevada is currently the only state to adopt laws that require adherence to these guidelines.

The 2018 AANEM Annual Meeting is taking place at the Gaylord National Resort & Convention Center in Washington, DC.

Funding needs to be more widely available to help implement these effective nonpharmacologic interventions.

Investigators pooled data from patients from 3 phase 3, 24-week, randomized, placebo-controlled trials of MEM in patients with Alzheimer disease receiving concurrent ChEIs.

The treatment may be beneficial in patients whose acute migraine does not respond to standard treatment with intravenous metoclopramide.

Dr Richard Lipton and Dr Paul Martin debated the pros and cons of trigger avoidance in patients with migraine headache at the 2018 American Headache Society Annual Scientific Meeting in San Francisco, California.

The investigators assessed participants for photophobia, unilateral location, phonophobia, exacerbation, nausea, pulsatility, sensory aura, pain level and frequency, visual aura, and allodynia features.

The CaMEO study is a prospective, longitudinal web-based survey designed to characterize the impact of migraine on aspects of quality of life.

While hundreds of published reports have made an argument for an association between Alzheimer disease and bacteria and viruses, the suggestion of a viral contribution to Alzheimer disease has not always been well received by the greater research community.

The first-in-class migraine prevention drug will be available to patients within 1 week of the approval.

Several prodromal symptoms in REM sleep behavior disorder are highly associated with conversion to neurodegenerative diseases.

A regression model showed that efficacy of DMTs significantly decreased until age 53, after which disease progression is not affected by DMTs.

Wearable technology may help monitor on/off states in patients with Parkinson disease in an outpatient setting.

The results suggest a noninvasive method for predicting individualized risk for certain stroke subtypes.

Patients in the 2 highest dosing groups saw significant, sustained improvements over the 12-week study.

The new guidelines focus on helping clinicians decide when to initiate, switch, or discontinue disease-modifying therapies for multiple sclerosis.

Researchers found that high doses of the novel antisense oligonucleotide were associated with lower concentrations of mutant huntingtin protein in the cerebrospinal fluid and brain.

Neurology Advisor will provide live coverage of the 2018 American Academy of Neurology Annual Meeting from Los Angeles, CA.

Further research should focus on establishing whether siponimod exerts its effect on the pathogenic processes associated with disease progression or activity, or both.

The FDA has expanded the treatment window for a clot retrieval device in certain patients presenting with acute ischemic stroke.

Both erenumab and fremanezumab are currently under review by the FDA for the treatment of migraine.

Clobazam is currently FDA-approved for the treatment of seizures associated with Lennox-Gastaut syndrome in children 2 years and older.

The diagnostic tool may be especially useful in cases of nonlesional mesial temporal lobe epilepsy.

Patients with refractory epilepsy who fail to benefit from 2 or more AEDs should be referred to alternative therapies.

Patients who died from suspected SUDEP had extensive damage to areas of the mid-brain and brainstem that control autonomic function.

Researchers compared outcomes between patients treated with continuous infusion or repeated doses of nonbenzodiazepine anti-seizure medication.

The study was a post-hoc analysis of responders who were on or off concomitant clobazam.

Patients undergoing treatment for ischemic stroke are at greater risk for seizure development.

Treatment with positive airway pressure may help retain or improve seizure control in patients with epilepsy and obstructive sleep apnea.

Preoperative cognitive function is a central component of predicting cognitive outcomes after resective epilepsy surgery.